**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 91355

**Manuscript Type:** MINIREVIEWS

**Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status**

Gupta T *et al*. HCC tumor microenvironment and checkpoint inhibitors

Tarana Gupta, Nikhil Sai Jarpula

**Tarana Gupta, Nikhil Sai Jarpula,** Division of Hepatology, Department of Medicine, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak 124001, Haryana, India

**Author contributions:** Gupta T wrote the paper and critically analyzed the manuscript; Jarpula NS collected the data and literature and drafted the manuscript.

**Corresponding author: Tarana Gupta, MBBS, MD, DM Hepatology, Professor, Researcher,** Division of Hepatology, Department of Medicine, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, House No. 1065A Sector 1, Rohtak 124001, Haryana, India. taranagupta@gmail.com

**Received:** December 27, 2023

**Revised:** January 24, 2024

**Accepted:** March 4, 2024

**Published online:**

**Abstract**

Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and has a high mortality rate. The Barcelona Clinic Liver Cancer staging system in addition to tumor staging also links the modality of treatment available to a particular stage. The recent description of the tumor microenvironment (TME) in HCC has provided a new concept of immunogenicity within the HCC. Virus-related HCC has been shown to be more immunogenic with higher expression of cytotoxic T lymphocytes and decreased elements for immunosuppression such as regulatory T cells. This immunogenic milieu provides a better response to immunotherapy especially immune checkpoint inhibitors (ICIs). In addition, the recent data on combining locoregional therapies and other strategies may convert the less immunogenic state of the TME towards higher immunogenicity. Therefore, data are emerging on the use of combinations of locoregional therapy and ICIs in unresectable or advanced HCC and has shown better survival outcomes in this difficult population.

**Key Words:** Hepatocellular carcinoma; Tumor immune microenvironment; Immune checkpoint inhibitor; Atezolizumab; Bevacizumab; Pembrolizumab

Gupta T, Jarpula NS. Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status. *World J Hepatol* 2024; In press

**Core Tip:** Hepatocellular carcinoma (HCC) is a prototype of inflammation-associated cancer. Its varied etiology from viral to alcohol and non-alcoholic steatohepatitis, tumor extent, intrahepatic spread, vascular invasion and metastases along with the underlying severity of liver dysfunction make it a complex scenario for adequate management. The recent elaboration of the tumor microenvironment revealing an immunogenic milieu and bringing the concept of “Cold” and “Hot” tumor opened the way for evaluation of immunotherapy in HCC. In recent years, with use of immune checkpoint inhibitors, there is a paradigm shift in the management of advanced and unresectable HCC. With the use of combination regimens including immune checkpoint inhibitors and transarterial chemoembolization/ablation/tyrosine kinase inhibitors, there is an ongoing effort to improve disease outcomes and minimize adverse events.

**INTRODUCTION**

Primary as well as metastatic carcinoma can be found in the liver. Liver cancer is the sixth most common cancer worldwide and ranks fourth in the list of cancer-related deaths. It has a dismal 5-year survival of 18%[1]. Hepatitis B which is a carcinogenic virus has remained among the most common causes of hepatocellular carcinoma (HCC), especially in China. However, with universal immunization programs and hepatitis C elimination programs, alcohol and metabolic dysfunction associated steatotic liver diseases are emerging etiologies of HCC worldwide.

The Barcelona Clinic Liver Cancer (BCLC)[2] guidelines, first proposed in 1999, are the most accepted and practiced guidelines for prognostication and management of HCC. The recent BCLC 2022 update[3] has further clarified the grey areas in different stages of HCC, downstaging of tumors, treatment stage migration and progression of HCC within the same stage. “Untreatable progression” represents failure of the selected treatment strategy or progression of disease but remains in the same stage resulting in the need for consideration of therapy for a more advanced stage. This led to new staging upon progression after initial diagnosis, which includes 3 groups BCLCp-B defined as initially stage B and progressed but remained in stage B, BCLCp-C1 shows growth of the existing lesion or new lesions in the liver only. If there is new vascular invasion or new extrahepatic sites of metastases this is considered BCLCp-C2.

The pathophysiology of HCC is intricately linked to chronic liver diseases, which are characterized by prolonged hepatocytic injury and inflammation resulting in repair and regeneration of hepatocytes. These repeated cycles of injury and repair lead to genetic mutations such as in telomerase reverse transcriptase, catenin beta-1, tumor protein 53 (TP53), axis inhibition protein 1, AT-rich interaction domain 1A (ARID1A) and ARID2[4,5]. These mutations affect the cell cycle control and wingless-related integration site (WNT)-beta-catenin pathway which in addition to epigenetic mechanisms result in activation of hepatocarcinogenic pathways. Unlike other solid tumors, no single gene mutation is attributable to HCC development. Systemic therapies have been an integral part of the management of advanced HCC (BCLC stage C), especially tyrosine kinase inhibitors (TKIs) [Sorafenib 2007 and lenvatinib (LEN) since 2018]. They have improved outcome in HCC[6-8] and other TKIs such as regorafenib and cabozantinib are used in the second-line treatment of advanced HCC.

Tumor growth and regression also depend on interaction of the immune system with cancer cells, where cancer cells employ mechanisms to evade the immune system such as by downregulating the major histocompatibility complex (MHC) or expressing the immune checkpoint proteins like programmed death receptor ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1). This has led to the development of therapies targeting these molecular and immune mechanisms.

**TUMOR IMMUNE MICROENVIRONMENT**

HCC is almost a prototype of inflammation-associated cancer. The tumor microenvironment (TME) has both cellular and non-cellular components. The cellular component has damaged hepatocytes, hepatic progenitor cells and different types of immune cells. The non-cellular component has tumor stroma with growth factors, inhibitory factors, proteolytic enzymes and both pro-inflammatory and anti-inflammatory cytokines. The TME is also dependent upon and modulated by the etiology of chronic liver disease, genetics, epigenetics and other factors related to cellular metabolism.

The liver plays a pivotal role in immune regulation with its large reservoir of immunocompetent cells including neutrophils, monocytes, Kupffer cells, natural killer (NK) cells, dendritic cells (DCs) and lymphocytes (B lymphocytes, CD4+, CD8+). To maintain homeostasis, the liver environment always has a balance between pro-inflammatory [Interleukin (IL)-2, IL-7, IL-12, IL-15, and interferon γ (IFN-γ)] and anti-inflammatory mechanisms [IL-10, IL-13, and transforming growth factor β (TGF-β)][9]. In chronic liver diseases, there is an inclination towards pro-inflammatory signals due to necroinflammation in hepatocytes. Also, the abnormal gut-microbiota-liver axis increases the risk of bacterial infections in patients with cirrhosis leading to the production of anti-inflammatory cytokines such as IL-10 by Kupffer cells and DCs in the liver which suppress the co-stimulatory molecules on antigen presenting cells preventing CD4+ T cells activation[10,11]. T cell mediated immunity is also decreased in chronic hepatitis B whereas hepatitis C evades the immune system of the host due to its high mutational rates and through viral factors that counteract DNA sensors[12,13]. Hence, the microenvironment in cirrhosis is a combination of inflammation and immunosuppression forming a safe niche for cancer cells to grow and counteract the immune mechanisms.

***Immune activation***

Due to tumor cell proliferation, necrosis and lately due to treatment, cancer cell antigens are released continuously. These antigens are captured by DCs through interaction with toll-like receptor (TLR)2 and TLR4. The DCs undergo maturation and under the influence of chemokines migrate to the lymph nodes[14,15]. Following the activation of co-stimulatory molecules CD40 on DCs, these antigens are presented to CD8+ cytotoxic T lymphocytes (CTLs) in lymph nodes. Additionally, CTLs are also activated by IFN-γ released from NK cells, TH1 cells and tumor necrosis factor (TNF)-α and IL-12 released from macrophages and chemokines (CXCL-9, CXCL-10, CCL-5). With the interaction between lymphocyte function associated antigen 1 on activated T lymphocytes and intercellular adhesion molecule 1, tumor cells can be infiltrated by CTLs. Subsequently with recognition of cancer cells by T cell receptors along with co-stimulatory receptors, activated CTLs kill the cancer cells[16] (Figure 1).

On the contrary, various check point molecules such as CTL-associated protein 4 and PD-1 bind to the CD80/86 molecule and interact with PD-L1 on DCs, respectively, and suppress the immune response. Immune-inhibiting cytokines such as IL-10, TGF-β, prostaglandin E2 (PGE2), and indoleamine 2,3-dioxygenase influence the expression of PD-1 on T cells and PD-L1 on DCs[17]. Additionally, vascular endothelial growth factor (VEGF) phosphatase and tensin homolog deleted on chromosome 10 produced by cancer cells activate the phosphotidylinositol 3/AKT pathway to suppress T cell infiltration[18].

***Immune suppression***

**Tumor associated neutrophils:** Neutrophils are a vital component of the immune system playing important roles during infection, injury and tumorigenesis. In the TME, tumor associated neutrophils (TANs) are recruited through the release of CXCL-5 and CXCL-6[19]. These neutrophils have a key role in tumor initiation, proliferation, progression and metastasis. The location of the neutrophils can be predominantly at the tumor periphery initially, and later within the tumor with different phenotypes initially anti-tumorigenic (N1) and later pro-tumorigenic (N2). Cancer associated fibroblasts (CAFs) modulate the expression of CXCL6 and TGF-β through cardiotrophin-like cytokine factor 1 by polarizing the TANs towards the pro-tumoral phenotype (N2). The N2 phenotype form neutrophil extracellular traps (NETs) which are released by a process of cell death called NETosis[20]. These NETs support tumor growth and increase invasiveness through activation of TLR-4/9-COX2. N2 TANs inhibit the activation or migration of neutrophils into the tumor through the PD-1/PD-L1 pathway[21]. Expression of CD66b, PD-L1, CCL-2, CXCL8, TNF-α, and elevation of CD66b+ neutrophils in the peritumoral region has shown decreased survival in HCC patients. Many studies have shown blocking NETs (by inhibiting COX2, inhibiting NETosis by inhibiting cathepsin G) decreased invasion and metastasis *in vitro*[22]. Studies have shown that TANs cause recruitment of macrophages and Treg cells within the tumor by secreting CCL-2 and CCL-17, resulting in resistance to sorafenib[23]. TME neutrophils act as a principal source for the production of prometastatic Oncostatin M and matrix metalloproteinase which promote angiogenesis by releasing pro-angiogenic factors leading to migration of cancer cells. Evasion of autophagy or delay in apoptosis of neutrophils in the TME is also associated with tumor growth and angiogenesis[24]. The extensive role of TANs reveals new horizons in our understanding of the cancer microenvironment and potential therapeutic options.

**DCs-the initiator**: DCs are unique cells for capturing pathogens or antigens from tumor cells and presenting them to naive T cells which leads to their differentiation into effector T cells marking the initiation of immune response. Based on the stage of differentiation and development, physiological and pathological environment, DCs are divided into (1) Conventional DCs (cDCs) also known as myeloid DCs (CD141+/CD14- type 1 cDCs and CD1c+/CD14- type 2 cDCs); (2) Plasmacytoid DCs (pDCs) (CD303+ CD304+, secreting type I IFN); and (3) Inflammatory DCs[25]. The interaction of DCs with other immune cells occurs in a sequential manner; DCs presenting antigen to CD4+Th cells through MHC class II and CD8+T cells through MHC class I, which results in a co-stimulatory molecular interaction leading to cytokine production that stimulates CD8+T cells differentiation and expansion[26]. Studies have observed that in patients with HCC, there is lowered expression of co-stimulatory molecules and decreased levels of cDCs and pDCs making the TME appropriate for tumor growth. In HCC, the presence of BDCA2+ pDCs increase infiltration of T regulatory cells, which secrete IL-10, and IL-17 producing cells into the tumor. In addition, pDCs and tumor cDCs express Gal9 (ligand of TIM3), PD-L1, MHC-II (for LAG3), and CD80 (for CTLA 4) inducing an immunosuppressive environment in the TME. Newer subsets of DCs (DC-c1-CD1C, DC-c3-CLEC9A, and DC-c4-LAMP3) have been found in treatment naive HCC patients with LAMP3+ DCs having a strong association with exhaustion/regulation of T cells.

The TME also diverts the process of dendropoiesis (DCs generation) and tends to polarize the phenotype of DCs which creates an immunosuppressive environment by acting against anti-tumor immunity[27]. Anti-tumor immunity enhancing strategies such as DC based vaccines or immunotherapies are under clinical trials and have shown better outcomes and an enhanced CD4+T cells/CD8+T cells ratio[28]. The profound impact of DCs on immune modulation may lead to the development of new immunotherapies.

**Tumor associated macrophages – a double edged sword:** Liver parenchyma has a high macrophage density. Cytokines influence macrophage differentiation into classically activated M1 (CD86+) macrophages performing pro-inflammatory functions and M2 (CD163+, CD206+) macrophages which suppress the immune system and perform tissue repair. Liver tumor associated macrophages (TAMs) are commonly associated with CD68+ as their marker[29]. In HCC, studies have shown that joint analysis of high level CD206+ M2 macrophages and low level CD86+ M1 macrophages is associated with aggressive HCC phenotype thus indicating their utility as a prognostic tool for HCC[30]. TAMs promote metastasis, anti-tumor immunity suppression, angiogenesis and drug resistance. The TME contains two different TAMs *i.e.* resident macrophages and infiltrating macrophages. Osteopontin/CSF1/CSF1R pathways are other mechanisms leading to the infiltration of macrophages and drug resistance[31]. Activation of M2 macrophages through the Wnt/β-catenin pathway may pose an increased risk for tumor progression in HCC. TAMs modulate the tumor structure, migration, invasion and metastasis through various cytokines such as IL-6, IL-10, TNF-α, VEGF and other signals inhibiting T cells, NK cells cytotoxicity, and differentiation of Tregs. Studies have documented an association between high levels of TAMs in the peri-tumoral region and poor prognosis of HCC[32]. TAMs with actions of M1 macrophages cause immune activation, phagocytosis, and apoptosis of tumor cells. Many newer immune combination therapies targeting these immune suppressive mechanisms are under trials.

**Monocytes and Myeloid derived suppressor cells:** Recruited through tumoral CCL-2 production, monocytes have antitumoral effects in the early stages of HCC and later the tumor cells evade monocyte induced death and cause progression of the tumor. In the TME monocytes are classified as CD14+ monocytes, CCR1+ CD14+ monocytes, and Myeloid derived suppressor cells-M type. In advanced stages of HCC, CD14+ monocytes due to the expression of PD-L1/2+, IL-10, and CCL-1 promoted an immunosuppressive environment in the TME[33]. The CCL-15 chemokine recruits the suppressive phenotype of monocytes and promotes immune escape of HCC by increased angiogenesis and metastasis[34].

Monocytes and Myeloid derived suppressor cells (MDSCs) are immature immune cells that suppress the antitumor immunity in tumors. Phenotypically, MDSCs are classified into two types - polymorphonuclear (PMNs) MDSC and monocytic MDSC[35]. They differ in their mechanism in which they mediate the immune suppression. PMN-MDSCs mediate through PGE2, arg-1, and ROS while M-MDSCs facilitate their action through immunosuppressive cytokines (IL-10 and TGF-β), nitric oxide and immunomodulatory molecules such as PD-L1. In HCC, the proportion of M-MDSCs is high, inhibiting NK cell cytotoxicity and inducing Tregs[36]. The TME in HCC is also modulated by MDSC through the production of angiogenic factors and other enzymes promoting angiogenesis and growth of the tumor.

**T regulatory cells-suppressors of anti-tumor immunity:** Tregs are a specialized subset of T lymphocytes having a distinctive role in the suppression of excessive immune response and mitigating inflammation. Tregs are classified into (1) Natural Tregs possessing (nucleus FOXP3, CD25 and CTLA-4 surface markers); and (2) Induced Tregs (FOXP3 and CD4+ markers)[37]. These cells modify the T cell activation, differentiation, proliferation and function of effector T cells by various genetic mechanisms. Infiltration of Tregs into the TME is influenced by chemokines CCL-17, 22 through the CCR4 receptor. Most CCR4+ Tregs are more immunosuppressive than CCR4- Tregs[38]. Many studies have shown that although Checkpoint inhibitors show a good response in HCC, a few individuals with resistance to immune therapy can be attributed to Treg cells (Figure 2).

**CAF:** These are Fibroblast-specialized cells with a role in the synthesis and maintenance of the extracellular matrix. CAFs are derived from mesenchymal lineage and contribute to tumor promoting inflammation and fibrosis. CAFs can differentiate from blood vessels, epithelial cells, pericytes, adipocytes *via* endothelial to mesenchymal transition[39]. In HCC, these fibroblasts can differentiate from cancer cells or vascular cells or from mesenchymal stem cells in bone marrow. Based on the expression of α-smooth muscle actin (α-SMA) and IL-6, two major phenotypes of CAFs are present (1) Myofibroblastic (myCAF); and (2) Inflammatory type (iCAF). The myCAF are more matrix-secreting, TGF-β–responsive with high α-SMA expression, and low-cytokine IL-6 and IL-11 production, and are localized in dense stroma near cancer cells. The iCAF exhibit high IL-6 and IL-11 production with low α-SMA expression and are localized in stroma away from cancer cells[40,41].

CAFs induce changes in the tumor by (1) Angiogenesis through production of VEGF, platelet derived growth factor and CXCL-12; (2) Invasion and metastasis; (3) Immune modulation by recruitment of immune suppressors and suppressors of anti-tumor immunity; and (4) Resistance to therapeutic modalities. CAFs in the TME shape the milieu of the tumor by generating pro-inflammatory cytokines including IL-1β and IL-6 and by expressing ligands CXCL12 and CXCL1 resulting in tumor promotion. The interaction of CAFs with other immune cells such as T cells, NK cells, MDSCs, DCs, TANs, and TAMs in the TME result in immunosuppression. The CAFs have a key role in promoting carcinogenesis of epithelial cells and inducing the generation of MDSC through the IL-3/STAT3 axis and SDF-1α which suppress antitumor immunity[42,43].

***Cold and hot tumors concept***

Based upon the inflammatory milieu of the TME, no T cell infiltrate, presence of regulatory cytokines, no PD-L1, and increased CAFs, increased MDSC population, the tumor is labeled as “COLD” and poorly responsive to immunotherapy[44]. On the other hand, increased T cell infiltrate, pro-inflammatory cytokines, high PD-L1, increased CD8+T cells, and increased TAMs, the tumor is labeled as “HOT” and is amenable to immunotherapy (Figure 3).

**IMMUNOTHERAPY IN HCC**

The primary treatment options for each HCC stage depends not only on the stage but also on the patient characteristics and profile of the patient. According to BCLC update 2022, systemic therapy is treatment of choice in patients with advanced stage (BCLC-C) HCC and in patients with stage A and B where other treatment options are not feasible or failed[3]. Immune therapy utilizes the body's natural defense mechanisms to combat tumor cells in any cancer. Immune checkpoints (ICs) are molecules present on lymphocytes which regulate the functions of T lymphocytes and influence tumor autoimmunity. Immune cells such as T cells, NK cells, and Tregs express PD-1 checkpoint molecules whereas stromal cells, myeloid cells, and tumor cells express PD-L1/PD-L2 which inhibit the functions of effector T cells and create an immunosuppressive environment. ICIs target these molecules expressed on immune cells to enhance autoimmunity in the TME.

***Current status***

Atezolizumab (Atez) is a monoclonal antibody against PD-1 and in combination with Bevacizumab (Bev) monoclonal antibody against the VEGF receptor has been approved as first-line therapy for advanced stage HCC (BCLC stage C). The IMbrave150 study[45] showed that the combination arm (Atez 1200 mg/Bev 15 mg/kg) resulted in overall survival (OS) at 12 months of 67.2% *vs* 54.6% in the sorafenib (400 mg BD) arm. Further analysis showed that the Atez/Bev combination resulted in an OS of 19.2 months *vs* 13.4 months and progression free survival (PFS) of 6.9 months *vs* 4.8 months in the sorafenib arm in unresectable HCC (uHCC), respectively[46]. The beneficial effects of the Atez/Bev combination arm were persistent across BCLC stage B or C, extrahepatic metastases and portal vein invasion. Grade 3 or 4 adverse events related to treatment occurred in 43% and 46% patients in the Atez/Bev combination and sorafenib, respectively. This was a landmark trial and led to FDA approval of this combination (Atez/Bev) in advanced HCC[47]. In a multi-centric retrospective real world evaluation of data, the Atez and Bev combination was well tolerated with no evidence of treatment related deaths or new adverse events across CP-A and CP-B patients with an OS of 14.9 months and PFS 6.8 months[48]. A systematic review of studies from 2002-2020 on systemic therapies in HCC (including all disease stages) examined the association between etiology of HCC and therapy outcomes. The results revealed that immunotherapies were more effective in viral etiologies as compared to non-viral etiologies as compared to TKIs/anti-VEGFs[49]. The viral etiology related HCC is more immunogenic and therefore, ICIs are more effective due to their favorable TME. On the other hand, non-alcoholic steatohepatitis (NASH) related HCC has been shown to accumulate exhausted CD8+PD1+T cells in the TME, and in preclinical models, anti-PD-1 therapy instead of tumor regression led to tumor progression in terms of size as well number of nodules[50]. Another systematic review[51] showed the non-inferiority of LEN to Atez/Bev in achieving an objective response rate (ORR) and disease control rate (DCR) in advanced HCC; however, data were insufficient for evaluation of OS.

The Himalaya trial evaluated the STRIDE regimen *i.e.* anti-CTLA4 inhibitor tremelimumab single dose (T300 mg) and anti-PD-L1 durvalumab (D1500 mg every 4 wk) in uHCC and found a significant increase in median OS by 2.5 months (16.4 months *vs* 13.8 months) as compared to sorafenib (400 mg BD) alone. They showed that a single priming dose of T was sufficient to enhance the efficacy of D in uHCC patients with no increased adverse drug events[52]. This ground-breaking trial led to the recommendation of tremelimumab and durvalumab as first-line therapy for uHCC.

If first-line therapies are not feasible or contraindicated for some reason, monotherapy with TKIs sorafenib/LEN or durvalumab (anti PD-L1) can be considered.

The KEYNOTE 224 phase II trial[53] documented the antitumor activity and safety of pembrolizumab therapy in patients with HCC previously treated with sorafenib. Subsequently, the multi-centric KEYNOTE 240 phase II trial[54] in HCC patients (previously treated with sorafenib) showed no significant difference in OS and PFS after pembrolizumab therapy. The recent KEYNOTE 394 multi-centric trial[55] from Asia, in HCC patients (post sorafenib or progression/intolerance on sorafenib) demonstrated significantly increased OS (14.6 months *vs* 13 months, *P* = 0.01) and PFS (2.6 months *vs* 2.3 months, *P* = 0.003) in the pembrolizumab group compared with placebo, respectively.

The CheckMate 040 phase I/II, non-comparative trial[56] showed safety data in patients with advanced HCC treated with nivolumab (anti-PD-1 inhibitor). The phase 3 trial CheckMate 459 compared nivolumab and sorafenib in advanced HCC and both groups had similar OS and PFS with no significant differences. The CheckMate 040 phase III RCT[57] showed improved ORR and durable response with the combination of nivolumab and ipilimumab therapy in advanced HCC (Table 1).

***Predictors of response to immunotherapy***

Pre-existing immunity *i.e.* intra-tumoral CD8+ Tcell density, high expression of CD274, low Treg to T effector cell ratio, low expression of oncofetal genes such as GPC3 and AFP, high expression of VEGF receptor 2 and myeloid inflammation signatures are predictors of response to the Atez/Bev combination regimen. Viral etiology related HCC is more immunogenic and therefore, is more responsive to ICIs.

***Combination therapies***

HCC is a complex tumor where multiple factors such as size of the primary tumor, intrahepatic spread, vascular invasion and metastatic disease need to be addressed. Additionally, liver dysfunction and its severity affect the feasibility of locoregional as well as systemic therapies. The combination of locoregional and systemic therapies has been evaluated in recent trials to improve overall outcomes (Table 2).

***ICI and transarterial chemoembolization***

A propensity score matched study compared the combination of transarterial chemoembolization (TACE) and Atez/Bev against the combination of TACE and LEN (LEN-TACE). They found that both groups showed comparable safety and efficacy in uHCC patients[58]. Another recent Chinese study[59] investigated the combination of TACE and Atez/Bev which resulted in significantly better ORR, OS and PFS as compared to Atez/Bev. The rationale for this, is that TACE decreases the primary tumor load and therefore, the burden of immunosuppressive Treg cells *etc.* and induces hypoxia in the TME. Therefore, CTLs increase in the TME and hypoxia induces an increase in VEGF expression and ICIs (Atez/Bev) have better action due to favorable conditions in the TME. For BCLC stage B, the recommended treatment modality is TACE. Switching to ICIs before deterioration of liver function in patients with BCLC stage B could improve their prognosis and survival. The REPLEC study[60] included HCC patients with BCLC stage B beyond up to seven criteria (unsuitable for TACE) UT-7/multiple/Child Pugh A treated with Atez/Bev who showed an ORR and DCR of RECIST and mRECIST of 17.7%/84.7% and 42.5%/86.2%, respectively.

***ICIs and TKIs***

The phase 1 KEYNOTE-524 trial[61] demonstrated that the LEN + pembrolizumab (PEM) combination resulted in a median PFS of 9.3 months, ORR of 46% by mRECIST, and median OS of 22 months in patients with uHCC in 29% of BCLC stage B (not suitable for TACE) and in 71% stage C patients. The rationale behind this combination was that LEN, due to its immunomodulatory effects, inhibits proangiogenic and immunosuppressive mechanisms in the TME and enhances the antitumor effects of pembrolizumab. However, the recent LEAP-002 phase 3 trial[62] failed to show any benefit of LEN + PEM combination therapy in uHCC.

***ICIs and Ablation***

A recent study demonstrated that tremelimumab (anti-CTLA4 Ab) combined with ablation achieved good anti-tumor activity due to enhanced CD8+T cells in the tumor periphery after ablation[63].

***ICIs and surgical resection of HCC***

Surgical resection in HCC is confined to BCLC very early stage and early stage of HCC (stage A). In advanced stages of uHCC, ICIs are used as bridging therapy for tumor downstaging, negative selection and as neoadjuvant therapy[64]. Downstaging of HCC refers to a shift in tumor stage to a lower level after immunotherapy when surgical intervention can be considered. Negative selection refers to a new concept of “absence of appearance of new lesions after immunotherapy with steady response.” This can be treated as localized disease and surgical options can be tried as definitive management. Neoadjuvant therapy is used to shrink the tumor size and allow wider safety margins during surgery. Neoadjuvant immunotherapy is administered for patients with either early resectable tumor or initially unresectable tumor for downstaging[65].

In a study involving 54 patients with uHCC, who received combination immunotherapy followed by radical surgery, pathological evaluation of postoperative specimens confirmed 21.4% (*n* = 3) of patients achieved a complete response and 78.6% (*n* = 11) achieved PR[66]. Zhang *et al*[67] reported 10 patients with HCC and major vascular invasion who achieved a 12-month recurrence-free survival rate of 75% after combinations of ICI and TKI with subsequent salvage surgery[67].

***Immune therapy related adverse events***

Tolerance of the immune system is the ability to prevent an immune response against a particular antigen. Immune therapy (ICIs) breaks the tolerance of the body’s immune system which produces immune related adverse events. Based on common terminology criteria for adverse events grading, the severity of immune therapy related adverse events (irAEs) are Grade 1 mild, Grade 2 moderate, Grade 3 severe, Grade 4 life threatening, Grade 5 death[68]. Inhibition of checkpoint molecules which prevent the tumor cells escaping the immune system can cause disruption in tolerance of the immune system (mainly peripheral T cells) leading to proliferation of immune cells and high inflammation and autoimmunity. Hence, most common sites involved would be skin and colon as they predominantly depend on peripheral T cell tolerance for maintaining immune homeostasis[69]. Other mechanisms of irAEs involve autoreactive B cells, cytokines and other host factors.

In HCC patients receiving ICIs, the incidence of irAEs is not higher than that in other carcinomas. The most common irAEs are skin manifestations, followed by gastrointestinal effects such as diarrhea. Hepatic irAEs include raised liver enzymes; however, they are grade 1 to 3 and are not life threatening. Patients with hepatitis B or C seropositive status are not prone to developing a flare if antiviral therapy is started and continued during ICI administration. However, CP-B patients due to their underlying severe liver dysfunction are more prone to severe irAEs. Nivolumab and pembrolizumab monotherapy in HCC patients resulted in rash and pruritus, which were the most common manifestations with an incidence of 11%-23% and 13%-19%, respectively. The incidence of colitis was 1% in patients treated with PD-L1 antibodies and 2.6% in patients treated with the combination of PD-L1 antibody and CTLA-4 antibody. Pneumonia was the main irAE with an incidence of 3% in patients treated with nivolumab[70]. Following tremelimumab therapy, grade 3 or higher encephalopathy was observed, but this may have been attributed to underlying cirrhosis than immunotherapy. Hypertension was observed to be the most common adverse event in patients treated with Atez/Bev with an incidence of 29.8%. Hypertensive encephalopathy, nephrotic syndrome, bleeding, myelosuppression and infection are severe irAEs in patients receiving Atez/Bev and these are influenced mostly by Bev. There is a need for vigilant monitoring to identify adverse events related to immunotherapy and prompt intervention is required for optimal patient outcomes.

**CHALLENGES WITH ICIs**

Tumor resistance to ICIs is a major challenge which is multifactorial and includes the following: (1) HCC mutational burden-total somatic mutations in HCC responsible for immune cells regulation; (2) Genetic pathways[71] (overactivation of beta-catenin) leading to decreased CD8+T cells infiltration and low PD-L1 expression in the TME; (3) TP53 inactivating mutations leading to ICIs resistance and tumor progression[72]; and (4) T cell exhaustion due to interaction of LAG 3 molecules and overexpressed FGL-1 in the TME[73].

**CONCLUSION**

ICIs have resulted in a paradigm shift in the management of advanced HCC. However, there is still a long way to go. There is a need to evaluate ICIs use in early HCC and to evaluate their role in downstaging of tumors for curative therapies such as resection or liver transplantation. Future strategies regarding other targets may overcome the ICI resistance seen in clinical practice. With upcoming NASH and obesity epidemics and NASH-HCC being less immunogenic with ICI resistance, it is necessary to determine how this low immunogenicity may be converted or reverted back to the immunogenic state to achieve ICI response. Cell based therapies or vaccines are other areas requiring research.

**REFERENCES**

1 **Jemal A**, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ, Weir HK. Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. *J Natl Cancer Inst* 2017; **109** [PMID: 28376154 DOI: 10.1093/jnci/djx030]

2 **Llovet JM**, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis* 1999; **19**: 329-338 [PMID: 10518312 DOI: 10.1055/s-2007-1007122]

3 **Reig M**, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. *J Hepatol* 2022; **76**: 681-693 [PMID: 34801630 DOI: 10.1016/j.jhep.2021.11.018]

4 **Guichard C**, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clément B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouzé E, Calvo F, Zucman-Rossi J. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. *Nat Genet* 2012; **44**: 694-698 [PMID: 22561517 DOI: 10.1038/ng.2256]

5 **Nault JC**, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C, Zucman-Rossi J. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. *Nat Commun* 2013; **4**: 2218 [PMID: 23887712 DOI: 10.1038/ncomms3218]

6 **Llovet JM**, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; **359**: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]

7 **Cheng AL**, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2009; **10**: 25-34 [PMID: 19095497 DOI: 10.1016/S1470-2045(08)70285-7]

8 **Kudo M**, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet* 2018; **391**: 1163-1173 [PMID: 29433850 DOI: 10.1016/S0140-6736(18)30207-1]

9 **Robinson MW**, Harmon C, O'Farrelly C. Liver immunology and its role in inflammation and homeostasis. *Cell Mol Immunol* 2016; **13**: 267-276 [PMID: 27063467 DOI: 10.1038/cmi.2016.3]

10 **Gao B**, Jeong WI, Tian Z. Liver: An organ with predominant innate immunity. *Hepatology* 2008; **47**: 729-736 [PMID: 18167066 DOI: 10.1002/hep.22034]

11 **Bamboat ZM**, Stableford JA, Plitas G, Burt BM, Nguyen HM, Welles AP, Gonen M, Young JW, DeMatteo RP. Human liver dendritic cells promote T cell hyporesponsiveness. *J Immunol* 2009; **182**: 1901-1911 [PMID: 19201843 DOI: 10.4049/jimmunol.0803404]

12 **Li XD**, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. *Proc Natl Acad Sci U S A* 2005; **102**: 17717-17722 [PMID: 16301520 DOI: 10.1073/pnas.0508531102]

13 **Meylan E**, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. *Nature* 2005; **437**: 1167-1172 [PMID: 16177806 DOI: 10.1038/nature04193]

14 **Böttcher JP**, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, Reis e Sousa C. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. *Cell* 2018; **172**: 1022-1037.e14 [PMID: 29429633 DOI: 10.1016/j.cell.2018.01.004]

15 **Barry KC**, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, Alvarado MD, Wolf DM, Bogunovic D, Bhardwaj N, Daud AI, Ha PK, Ryan WR, Pollack JL, Samad B, Asthana S, Chan V, Krummel MF. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. *Nat Med* 2018; **24**: 1178-1191 [PMID: 29942093 DOI: 10.1038/s41591-018-0085-8]

16 **Chen DS**, Mellman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity* 2013; **39**: 1-10 [PMID: 23890059 DOI: 10.1016/j.immuni.2013.07.012]

17 **Iñarrairaegui M**, Melero I, Sangro B. Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes. *Clin Cancer Res* 2018; **24**: 1518-1524 [PMID: 29138342 DOI: 10.1158/1078-0432.CCR-17-0289]

18 **Peng W**, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL Jr, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. *Cancer Discov* 2016; **6**: 202-216 [PMID: 26645196 DOI: 10.1158/2159-8290.CD-15-0283]

19 **Jaillon S**, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. *Nat Rev Cancer* 2020; **20**: 485-503 [PMID: 32694624 DOI: 10.1038/s41568-020-0281-y]

20 **Yang LY**, Luo Q, Lu L, Zhu WW, Sun HT, Wei R, Lin ZF, Wang XY, Wang CQ, Lu M, Jia HL, Chen JH, Zhang JB, Qin LX. Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma via provoking tumorous inflammatory response. *J Hematol Oncol* 2020; **13**: 3 [PMID: 31907001 DOI: 10.1186/s13045-019-0836-0]

21 **Sun R**, Xiong Y, Liu H, Gao C, Su L, Weng J, Yuan X, Zhang D, Feng J. Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis. *Transl Oncol* 2020; **13**: 100825 [PMID: 32698059 DOI: 10.1016/j.tranon.2020.100825]

22 **Guan X**, Lu Y, Zhu H, Yu S, Zhao W, Chi X, Xie C, Yin Z. The Crosstalk Between Cancer Cells and Neutrophils Enhances Hepatocellular Carcinoma Metastasis via Neutrophil Extracellular Traps-Associated Cathepsin G Component: A Potential Therapeutic Target. *J Hepatocell Carcinoma* 2021; **8**: 451-465 [PMID: 34046369 DOI: 10.2147/JHC.S303588]

23 **Zhou SL**, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB, Fan J, Cao Y, Dai Z, Zhou J. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib. *Gastroenterology* 2016; **150**: 1646-1658.e17 [PMID: 26924089 DOI: 10.1053/j.gastro.2016.02.040]

24 **Li XF**, Chen DP, Ouyang FZ, Chen MM, Wu Y, Kuang DM, Zheng L. Increased autophagy sustains the survival and pro-tumourigenic effects of neutrophils in human hepatocellular carcinoma. *J Hepatol* 2015; **62**: 131-139 [PMID: 25152203 DOI: 10.1016/j.jhep.2014.08.023]

25 **Kunitani H**, Shimizu Y, Murata H, Higuchi K, Watanabe A. Phenotypic analysis of circulating and intrahepatic dendritic cell subsets in patients with chronic liver diseases. *J Hepatol* 2002; **36**: 734-741 [PMID: 12044522 DOI: 10.1016/s0168-8278(02)00062-4]

26 **Thaiss CA**, Semmling V, Franken L, Wagner H, Kurts C. Chemokines: a new dendritic cell signal for T cell activation. *Front Immunol* 2011; **2**: 31 [PMID: 22566821 DOI: 10.3389/fimmu.2011.00031]

27 **Enk AH**, Jonuleit H, Saloga J, Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. *Int J Cancer* 1997; **73**: 309-316 [PMID: 9359474 DOI: 10.1002/(sici)1097-0215(19971104)73:3<309::aid-ijc1>3.0.co;2-3]

28 **Chen C**, Ma YH, Zhang YT, Zhang F, Zhou N, Wang X, Liu T, Li YM. Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: A systematic review and meta-analysis. *Cytotherapy* 2018; **20**: 975-989 [PMID: 30072299 DOI: 10.1016/j.jcyt.2018.06.002]

29 **Huang Y**, Ge W, Zhou J, Gao B, Qian X, Wang W. The Role of Tumor Associated Macrophages in Hepatocellular Carcinoma. *J Cancer* 2021; **12**: 1284-1294 [PMID: 33531974 DOI: 10.7150/jca.51346]

30 **Dong P**, Ma L, Liu L, Zhao G, Zhang S, Dong L, Xue R, Chen S. CD86⁺/CD206⁺, Diametrically Polarized Tumor-Associated Macrophages, Predict Hepatocellular Carcinoma Patient Prognosis. *Int J Mol Sci* 2016; **17**: 320 [PMID: 26938527 DOI: 10.3390/ijms17030320]

31 **Zhu Y**, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, Li CW, Lim SO, Sheng YY, Zhang Y, Li JH, Luo Q, Zheng Y, Zhao Y, Lu L, Jia HL, Hung MC, Dong QZ, Qin LX. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. *Gut* 2019; **68**: 1653-1666 [PMID: 30902885 DOI: 10.1136/gutjnl-2019-318419]

32 **Zhu XD**, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY, Sun HC. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. *J Clin Oncol* 2008; **26**: 2707-2716 [PMID: 18509183 DOI: 10.1200/JCO.2007.15.6521]

33 **Yasuoka H**, Asai A, Ohama H, Tsuchimoto Y, Fukunishi S, Higuchi K. Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis. *Sci Rep* 2020; **10**: 10377 [PMID: 32587357 DOI: 10.1038/s41598-020-67497-2]

34 **Liu LZ**, Zhang Z, Zheng BH, Shi Y, Duan M, Ma LJ, Wang ZC, Dong LQ, Dong PP, Shi JY, Zhang S, Ding ZB, Ke AW, Cao Y, Zhang XM, Xi R, Zhou J, Fan J, Wang XY, Gao Q. CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma. *Hepatology* 2019; **69**: 143-159 [PMID: 30070719 DOI: 10.1002/hep.30134]

35 **Veglia F**, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. *Nat Rev Immunol* 2021; **21**: 485-498 [PMID: 33526920 DOI: 10.1038/s41577-020-00490-y]

36 **Hoechst B**, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten TF, Korangy F. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. *Hepatology* 2009; **50**: 799-807 [PMID: 19551844 DOI: 10.1002/hep.23054]

37 **Workman CJ**, Szymczak-Workman AL, Collison LW, Pillai MR, Vignali DA. The development and function of regulatory T cells. *Cell Mol Life Sci* 2009; **66**: 2603-2622 [PMID: 19390784 DOI: 10.1007/s00018-009-0026-2]

38 **Gao Y**, You M, Fu J, Tian M, Zhong X, Du C, Hong Z, Zhu Z, Liu J, Markowitz GJ, Wang FS, Yang P. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B. *J Hepatol* 2022; **76**: 148-159 [PMID: 34689996 DOI: 10.1016/j.jhep.2021.08.029]

39 **Erez N**, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. *Cancer Cell* 2010; **17**: 135-147 [PMID: 20138012 DOI: 10.1016/j.ccr.2009.12.041]

40 **Liu T**, Han C, Wang S, Fang P, Ma Z, Xu L, Yin R. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. *J Hematol Oncol* 2019; **12**: 86 [PMID: 31462327 DOI: 10.1186/s13045-019-0770-1]

41 **Öhlund D**, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, Chio II, Hwang CI, Tiriac H, Baker LA, Engle DD, Feig C, Kultti A, Egeblad M, Fearon DT, Crawford JM, Clevers H, Park Y, Tuveson DA. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. *J Exp Med* 2017; **214**: 579-596 [PMID: 28232471 DOI: 10.1084/jem.20162024]

42 **Deng Y**, Cheng J, Fu B, Liu W, Chen G, Zhang Q, Yang Y. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells. *Oncogene* 2017; **36**: 1090-1101 [PMID: 27593937 DOI: 10.1038/onc.2016.273]

43 **Biffi G**, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, Preall J, Tuveson DA. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. *Cancer Discov* 2019; **9**: 282-301 [PMID: 30366930 DOI: 10.1158/2159-8290.CD-18-0710]

44 **Ailia MJ**, Heo J, Yoo SY. Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment. *Int J Mol Sci* 2023; **24** [PMID: 37047482 DOI: 10.3390/ijms24076495]

45 **Finn RS**, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *N Engl J Med* 2020; **382**: 1894-1905 [PMID: 32402160 DOI: 10.1056/NEJMoa1915745]

46 **Salem R**, Li D, Sommer N, Hernandez S, Verret W, Ding B, Lencioni R. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial. *Cancer Med* 2021; **10**: 5437-5447 [PMID: 34189869 DOI: 10.1002/cam4.4090]

47 **Casak SJ**, Donoghue M, Fashoyin-Aje L, Jiang X, Rodriguez L, Shen YL, Xu Y, Jiang X, Liu J, Zhao H, Pierce WF, Mehta S, Goldberg KB, Theoret MR, Kluetz PG, Pazdur R, Lemery SJ. FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma. *Clin Cancer Res* 2021; **27**: 1836-1841 [PMID: 33139264 DOI: 10.1158/1078-0432.CCR-20-3407]

48 **D'Alessio A**, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Gaillard VE, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Personeni N, Pressiani T, Sharma R, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. *Hepatology* 2022; **76**: 1000-1012 [PMID: 35313048 DOI: 10.1002/hep.32468]

49 **Haber PK**, Puigvehí M, Castet F, Lourdusamy V, Montal R, Tabrizian P, Buckstein M, Kim E, Villanueva A, Schwartz M, Llovet JM. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020). *Gastroenterology* 2021; **161**: 879-898 [PMID: 34126063 DOI: 10.1053/j.gastro.2021.06.008]

50 **Pfister D**, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. *Nature* 2021; **592**: 450-456 [PMID: 33762733 DOI: 10.1038/s41586-021-03362-0]

51 **Giri S**, Angadi S, Vaidya A, Singh A, Roy A, Sundaram S. Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis. *Clin Exp Hepatol* 2023; **9**: 228-235 [PMID: 37790692 DOI: 10.5114/ceh.2023.130748]

52 **Abou-Alfa GK,** Chan SL, Kudo M, Lau G, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, Rimassa L, Breder VV, Vasilyev A, Heurgue A, Tam V, Mody K, Thungappa SC, He P, Negro A, Sangro B. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. *J Clin Oncol* 2022; **40**: 379–379 [DOI: 10.1200/JCO.2022.40.4\_suppl.379]

53 **Zhu AX**, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. *Lancet Oncol* 2018; **19**: 940-952 [PMID: 29875066 DOI: 10.1016/S1470-2045(18)30351-6]

54 **Finn RS**, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL; KEYNOTE-240 investigators. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. *J Clin Oncol* 2020; **38**: 193-202 [PMID: 31790344 DOI: 10.1200/JCO.19.01307]

55 **Qin S**, Chen Z, Fang W, Ren Z, Xu R, Ryoo BY, Meng Z, Bai Y, Chen X, Liu X, Xiao J, Ho GF, Mao Y, Wang X, Ying J, Li J, Zhong W, Zhou Y, Siegel AB, Hao C. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial. *J Clin Oncol* 2023; **41**: 1434-1443 [PMID: 36455168 DOI: 10.1200/JCO.22.00620]

56 **El-Khoueiry AB**, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet* 2017; **389**: 2492-2502 [PMID: 28434648 DOI: 10.1016/S0140-6736(17)31046-2]

57 **Yau T**, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, Ruth He A, El-Rayes BF, Acosta-Rivera M, Lim HY, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. *JAMA Oncol* 2020; **6**: e204564 [PMID: 33001135 DOI: 10.1001/jamaoncol.2020.4564]

58 **Zhao C**, Xiang Z, Li M, Wang H, Liu H, Yan H, Huang M. Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study. *J Hepatocell Carcinoma* 2023; **10**: 1195-1206 [PMID: 37521029 DOI: 10.2147/JHC.S418256]

59 **Cao F**, Shi C, Zhang G, Luo J, Zheng J, Hao W. Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study. *BMC Cancer* 2023; **23**: 873 [PMID: 37718456 DOI: 10.1186/s12885-023-11389-x]

60 **Hiraoka A**, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan. Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis. *Hepatol Res* 2022; **52**: 308-316 [PMID: 34799975 DOI: 10.1111/hepr.13734]

61 **Finn RS**, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. *J Clin Oncol* 2020; **38**: 2960-2970 [PMID: 32716739 DOI: 10.1200/JCO.20.00808]

62 **Llovet JM**, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. *Lancet Oncol* 2023; **24**: 1399-1410 [PMID: 38039993 DOI: 10.1016/S1470-2045(23)00469-2]

63 **Duffy AG**, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. *J Hepatol* 2017; **66**: 545-551 [PMID: 27816492 DOI: 10.1016/j.jhep.2016.10.029]

64 **Hsu HM**, Tsai HI, Lee WC, Wang CC, Yu MC, Lin SM, Lin CY, Wu CH, Lee CW. The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors. *J Hepatocell Carcinoma* 2023; **10**: 1873-1880 [PMID: 37901716 DOI: 10.2147/JHC.S433598]

65 **Pinato DJ**, Fessas P, Sapisochin G, Marron TU. Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma. *Hepatology* 2021; **74**: 483-490 [PMID: 33369758 DOI: 10.1002/hep.31697]

66 **Xue JS,** Liu H, Li RZ, Tan SY, Yan YC, Dong ZR, Hong JG, Liu EY, Zhang QB, Chen ZQ, Wang DX, Li T. Salvage surgery after combination immunotherapy for initially unresectable or metastastic hepatocellular carcinoma: A retrospective clinical study. *Clin Surg Oncol* 2023; **2**: 100025 [DOI: 10.1016/j.cson.2023.100025]

67 **Zhang W**, Hu B, Han J, Wang Z, Ma G, Ye H, Yuan J, Cao J, Zhang Z, Shi J, Chen M, Wang X, Xu Y, Cheng Y, Tian L, Wang H, Lu S. Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients. *Front Oncol* 2021; **11**: 747950 [PMID: 34737958 DOI: 10.3389/fonc.2021.747950]

68 **Freites-Martinez A**, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. *Actas Dermosifiliogr (Engl Ed)* 2021; **112**: 90-92 [PMID: 32891586 DOI: 10.1016/j.ad.2019.05.009]

69 **Lee DJ**, Lee HJ Jr, Farmer JR, Reynolds KL. Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors. *Curr Cardiol Rep* 2021; **23**: 98 [PMID: 34196833 DOI: 10.1007/s11886-021-01530-2]

70 **Cui TM**, Liu Y, Wang JB, Liu LX. Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma. *Onco Targets Ther* 2020; **13**: 11725-11740 [PMID: 33235462 DOI: 10.2147/OTT.S279858]

71 **Morita M**, Nishida N, Aoki T, Chishina H, Takita M, Ida H, Hagiwara S, Minami Y, Ueshima K, Kudo M. Role of β-Catenin Activation in the Tumor Immune Microenvironment and Immunotherapy of Hepatocellular Carcinoma. *Cancers (Basel)* 2023; **15** [PMID: 37190239 DOI: 10.3390/cancers15082311]

72 **Blagih J**, Buck MD, Vousden KH. p53, cancer and the immune response. *J Cell Sci* 2020; **133** [PMID: 32144194 DOI: 10.1242/jcs.237453]

73 **Wang J**, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, Chen L, Chen Y, Zhu G, Yin W, Zheng L, Zhou T, Badri T, Yao S, Zhu S, Boto A, Sznol M, Melero I, Vignali DAA, Schalper K, Chen L. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. *Cell* 2019; **176**: 334-347.e12 [PMID: 30580966 DOI: 10.1016/j.cell.2018.11.010]

**Footnotes**

**Conflict-of-interest statement:** No conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** Indian National Association for Study of Liver Diseases, No. 1319; American Association for The Study of Liver Diseases, No. 226223.

**Peer-review started:** December 27, 2023

**First decision:** January 13, 2024

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Li YW, China; Zhao H, China **S-Editor:** Fan JR **L-Editor:** Webster JR **P-Editor:**

**Figure Legends**



**Figure 1 Immune activation in the tumor microenvironment.** Interaction between tumor cells and the immune system is demonstrated in this figure. Antigen presentation by dendritic cells (antigen presenting cells) leads to activation of cytotoxic T lymphocytes which eventually leads to death of tumor cells by the release of granzymes and perforins. Activation of cytotoxic T cells require additional co-stimulatory signals during the interaction between dendritic cells and cytotoxic CD8+ T lymphocytes.PD-1: Programmed death receptor-1; PD-L1: Programmed death receptor ligand-1; ICI: Immune checkpoint inhibitor; TCR: T-cell receptor; MHC-1: Major histocompatibility complex I.



**Figure 2 Immune suppression in the tumor microenvironment. An i**mmunosuppressive environment is brought about by the interaction of various immune cells in the tumor microenvironment (TME). N2 pro-tumorigenic tumor associated neutrophils (TANs) influence Tregs and T cells by various chemokines such as CCL-2, CCL-17 and interleukin (IL)-8, tumor necrosis factor, respectively. M2 tumor associated macrophages modulate the TME by influencing Tregs, natural killer (NK) cells and T lymphocytes through IL-6, vascular endothelial growth factor and IL-10, respectively. M type myeloid derived suppressor cells inhibit the NK cells and influence Tregs through IL-6. Cancer associated fibroblasts modulate the effect of N2 TANs *via* IL-6. Dendritic cells also play a role in the TME by regulating Tregs. CAFs: Cancer associated fibroblasts; PD-1: Programmed death receptor-1; PD-L1: programmed death receptor ligand-1; pDC: Dendritic cell; M-MDSC: Monocytic myeloid derived suppressor cells; NK cell: Natural killer cell; VEGF: Vascular endothelial growth factor; TAN: Tumor associated neutrophils; TAM: Tumor associated macrophages; Tregs: Regulatory T cells; IL: Interleukin.



**Figure 3 Tumor microenvironment balance.** Depicted is the inclination of the tumor microenvironment towards an immunosuppressive environment and its components. NK cell: Natural killer cell; TAN: Tumor associated neutrophils; TAM: Tumor associated macrophages; Treg: Regulatory T cells; MDSC: Myeloid derived suppressor cells.

**Table 1 Clinical studies on immunotherapy**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **No.** | **Ref.** | **Study characteristics** | **Intervention**  | **Patient characteristics** | **Outcome** |
| 1 | IMbrave 150[45] | Phase III, Open label RCT | Group I Atez/Bev. Group II SOR | 501 BCLC-C, uHCC CP-A, ECOG 0/1 | OS: Gp I *vs* II-67% *vs* 54%. PFS: Gp I *vs* II-6.8 months *vs* 4.3 months |
| 2 | Multi-centric (Real world data)[48] | Retrospective  | Atez/Bev | 216 BCLC-C, uHCC m-HCC | mOS-14.9 months; mPFS-6.8 months; ORR (RECIST)-25%; DCR-73% |
| 3 | Himalaya[52] | Phase III RCT | STRIDE regime Treme/Durva. Durva alone. Treme alone. SOR alone | 1171, BCLC-C, uHCC | mOS: STRIDE *vs* SOR (16.3 months *vs* 13.7 months). ORR: STRIDE *vs* Durva (20.1 *vs* 17%). DCR: STRIDE *vs* Durva *vs* SOR (60.1% *vs* 54.8% *vs* 60.7%) |
| 4 | Keynote 224[53] | Phase II, Open label | Pembrolizumab | 104, BCLC-C, CP-A ECOG 0/1 | ORR-17% |
| 5 | Keynote-240[54] | Phase III, Double blind RCT | PEM *vs* Placebo | 413, BCLC-C | mOS: PEM *vs* Placebo (13.8 months *vs* 10.6 months). mPFS: PEM *vs* Placebo (3 months *vs* 2.8 months) |
| 6 | Keynote-394[55] | Phase III, Double blind RCT | PEM *vs* Placebo | 453, BCLC-C | mOS: PEM *vs* Placebo (14.6 months *vs* 13 months). mPFS: PEM *vs* Placebo (2.6 months *vs* 2.3 months) |
| 7 | Check-Mate 040[56] | Phase I/II Open label Noncomparative | Nivolumab | 262, BCLC-C CP-A/B ECOG 0/1 | ORR: Dose expansion phase 20%. Dose escalation phase 15% |

Atez/Bev: Atezolizumab + Bevacizumab; SOR: Sorafenib; RCT: Randomized control study; uHCC: Unresectable HCC; ECOG: Eastern Cooperative Oncology Group; CTP: Child-Turcotte-Pugh; BCLC: Barcelona Clinic Liver Cancer; mHCC: Metastatic hepatocellular carcinoma; OS: Overall survival; PFS: Progression free survival; mOS: Median overall survival; mPFS: Median progression free survival; Treme: Tremelimumab; Durva: Durvalumab; PEM: Pembrolizumab; NIV: Nivolumab; ORR: Objective response rate; DCR: Disease control rate

**Table 2 Clinical studies on combination therapies of immunotherapy with locoregional/tyrosine kinase inhibitors**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **No.** | **Ref.**  | **Study characteristics** | **Intervention**  | **Patient characteristics** | **Outcome**  |
| 1 | Propensity score matched study[58] | Retrospective study | Group I: TACE + Atez/Bev. Group II: TACE + LEN | 98, BCLC-C, uHCC | ORR: 12 months. Group I-75%; Group II-79%. mPFS: Group I-7.03 months; Group II-6.03 months. No significant difference in ORR and DCR |
| 2 | Chinese study[59] | Retrospective study | Group I: TACE + Atez/Bev. Group II: Atez/Bev only | 139, BCLC-C | ORR: Group I-38%; Group II-16.9%. mOS: Group I-14 months; Group II-10 months. mPFS: Group I-10 months; Group II-6 months |
| 3 | Keynote-524[61] | Open label Multi-centric study | LEN + PEM | 104, uHCC | ORR: mRECIST-46%; RECIST-36%. mPFS: mRECIST-9.3 months; RECIST-8.6 months |
| 4 | LEAP 002[62] | Double blind, Randomized control study | Group I: LEN + PEM. Group II: LEN + Placebo | uHCC, CP-A ECOG 0/1 | mOS: Group I-21.2 months; Group II-19.0 months. mPFS: Group I-8.2 months; Group II-8.0 months |
| 5 | REPLEC study[60] | Multi-centric analysis | Atez/Bev | 52, uHCC classified as UT-7, CP-A ECOG0/1 | ORR at 6 wk: RECIST-17.7%; mRECIST-42.5%. DCR at 6 wk: RECIST-84.7%; mRECIST-86.2%; mPFS-8 months |

TACE: Transarterial chemoembolization; Atez/Bev: Atezolizumab + Bevacizumab; SOR: Sorafenib; RCT: Randomized control study; uHCC: Unresectable hepatocellular carcinoma; ECOG: Eastern Cooperative Oncology Group; CTP: Child-Turcotte-Pugh; BCLC: Barcelona Clinic Liver Cancer; mHCC: Metastatic hepatocellular carcinoma; OS: Overall survival; PFS: Progression free survival; mOS: Median overall survival; mPFS: Median progression free survival; LEN: Lenvatinib; Treme: Tremelimumab; Durva: Durvalumab; PEM: Pembrolizumab; ORR: Objective response rate; DCR: Disease control rate.